Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces First Patient Dosed in Phase 2 Clinical Trial of MAR002, a Potential Best-in-disease Investigational Therapy for the Treatment of Acromegaly
Key Highlights
- ➤MAR002 Phase 2 trial doses first acromegaly patient
- ➤Study targets approximately 72 participants across three dose arms
- ➤Primary endpoint measures IGF-1 reduction after 10 weeks
- ➤Phase 1 showed deep, durable IGF-1 suppression and potentially biweekly dosing
- ➤MAR001 remains in Phase 2b development for severe hypertriglyceridemia
Expert Statements
Josh Lehrer, M.D., President and Chief Operating Officer of Lisata Therapeutics and Chief Executive Officer of Marea Therapeutics
“Treating our first acromegaly patient with MAR002 represents an important milestone for Marea Therapeutics”
Josh Lehrer, M.D., President and Chief Operating Officer of Lisata Therapeutics and Chief Executive Officer of Marea Therapeutics
“We believe MAR002 has a potential best-in-class profile and, if approved, could be transformative for the majority of acromegaly patients who cannot achieve disease control with current therapies.”
Josh Lehrer, M.D., President and Chief Operating Officer of Lisata Therapeutics and Chief Executive Officer of Marea Therapeutics
“We are focused on clinical execution to rapidly advance this product candidate to acromegaly patients who need new treatment options.”
Jill Sisco, President of Acromegaly Community, Inc.
“People living with acromegaly often face years of symptoms before receiving a diagnosis, and even after diagnosis, many continue to struggle with the long-term burden of managing this chronic disease”
Jill Sisco, President of Acromegaly Community, Inc.
“The advancement of new treatment options that have the potential to provide effective disease control while reducing treatment burden offers hope for the acromegaly community.”
Jill Sisco, President of Acromegaly Community, Inc.
“We are encouraged to see continued investment in investigational therapies like MAR002 that aim to address the needs and priorities of people living with this condition and expand treatment options.”
Trial follows promising MAR002 Phase 1 clinical trial results that demonstrated deep and durable IGF-1 suppression with PK properties that may enable dosing as infrequently as once every two weeks, compared to the daily subcutaneous injections required by the current standard of care
By directly blocking growth hormone signaling at the receptor level, MAR002 has the potential to deliver meaningful biochemical control for a broad population of acromegaly patients
Get started
Create a free account to read the full story.